EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunohistochemical testing of GISTs using CD117 markers: the UK NEQAS ICC & ISH external quality assessment data show significant differences in the performance of methods in regular use

Andrew Dodson, Suzanne Parry

British Journal of Biomedical Science · 17.07.2026 · 83

DOI: 10.3389/bjbs.2026.16506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Biomedical Science, online erschienen am 17.07.2026. Verfasst von Andrew Dodson und 1 weiteren Autor:innen. Beteiligte Einrichtung: UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ-Hybridisation (UK NEQAS ICC & ISH), London, United Kingdom. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-kit, Gastrointestinal Stromal Tumors, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD117 (c-KIT) is a tyrosine kinase receptor protein, mutations in which are important in the tumourigenesis of gastrointestinal stromal tumour (GIST). Immunohistochemical detection of CD117 is the primary identifying feature in its diagnosis.

Introduction

UK NEQAS ICC & ISH conducts an EQA programme for CD117 expression in GIST. Between May-2020 and May-2025, 20 runs of this EQA were undertaken. The archived data was analysed to look for evidence regarding the quality of testing and associations between primary antibodies and stain quality.

Discussion

Total submissions were 2,656 (mean per run = 132.8; range = 125–140). The number of submissions awarded a quality score indicating at least acceptable stain quality was 2,642 (99.5%). The total number of submissions that failed was 14 (mean proportion per run = 0.5%; range = 0.0%–2.4%); those obtaining a borderline score totalled 158 (mean proportion = 5.9%; range = 0.7%–10.9%); those obtaining an acceptable score totalled 394 (mean proportion = 14.8%; range = 4.3–24.4%); and those obtaining a good/excellent score totalled 2,090 (mean proportion = 78.7%; range = 57.7%–94.2%). There was a strong trend for the proportion of submissions obtaining a good/excellent quality score to increase over time. Four primary antibodies were used: Clone 9.7 (102 submissions, 3.9%), YR145 (263 submissions, 10.0%), EP10 supplied by Leica Biosystems (EP10(LB), 415 submissions, 15.8%), EP10 supplied by Roche Diagnostics (EP10(RD), 505 submissions, 19.2%), and a polyclonal antiserum supplied by Agilent Dako (1,263 submissions, 48.1%). A total of 76 submissions (2.9%) that used other primaries or suppliers were excluded from analysis.

Conclusion

Demonstration of CD117 overexpression in GIST was undertaken to a very high quality standard in the majority of laboratories. For users of Dako Agilent supplied automation the highest quality staining was produced by using the polyclonal antiserum from the same supplier. Among users of Leica Biosystems and Roche Diagnostics automation the best staining was produced by using primary sourced from the same supplier that provided their automation. It is recommended that Clone 9.7 (Roche Diagnostics) should not be used as the results it produced were statistically significantly inferior to those of all other antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-kitGastrointestinal Stromal TumorsImmunohistochemistryBiomarkers, TumorHumansUnited Kingdom

Stichwörter der Autor:innen

CD117EQAGISTexternal quality assessmentimmunohistochemistryquality

Substanzen

Proto-Oncogene Proteins c-kitBiomarkers, TumorKIT protein, human

Autor:innen und Institutionen

  • UK National External Quality Assessment Scheme for Immunocytochemistry and In-Situ-Hybridisation (UK NEQAS ICC & ISH), London, United Kingdom.

Zitieren

APA

Dodson, A., & Parry, S. (2026). Immunohistochemical testing of GISTs using CD117 markers: the UK NEQAS ICC & ISH external quality assessment data show significant differences in the performance of methods in regular use. British Journal of Biomedical Science, 83. https://doi.org/10.3389/bjbs.2026.16506

Vancouver

Dodson A, Parry S. Immunohistochemical testing of GISTs using CD117 markers: the UK NEQAS ICC & ISH external quality assessment data show significant differences in the performance of methods in regular use. British Journal of Biomedical Science. 2026;83. doi:10.3389/bjbs.2026.16506

BibTeX
@article{Dodson2026,
  author = {Dodson, Andrew and Parry, Suzanne},
  title = {Immunohistochemical testing of GISTs using CD117 markers: the UK NEQAS ICC & ISH external quality assessment data show significant differences in the performance of methods in regular use},
  journal = {British Journal of Biomedical Science},
  year = {2026},
  volume = {83},
  doi = {10.3389/bjbs.2026.16506}
}
Kostenlos starten →